“Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” (2025) Althea Medical Journal, 12(3), pp. 161–171. doi:10.15850/amj.v12n3.4209.